Terazosin And Metabolic Engagement in Alzheimer's Disease
The TAME-AD trial will be a randomized, double-blind, placebo-controlled Phase IIa clinical trial to evaluate the metabolic target engagement of terazosin for the treatment of Alzheimer's disease.
Male or female, aged 50-80 years (inclusive) at the time of consent. [+4]
Unwilling or unable to provide written informed consent or - where decisional ca... [+29]